IRWD
IRONWOOD PHARMACEUTICALS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.56
+1.71%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.53
From 52W high−33.95%
Volume1.68M
Market cap$588.25M
P/E (TTM)4.5x
P/S (TTM)1.5x
Div yield—
Key dataOct 19, 2026
Open
$3.53
From 52W high
−33.95%
Volume
1.68M
Market cap
$588.25M
ValuationView details →
P/E (Fwd)
2.8x
EV/EBITDA
3.7x
P/E (TTM)
4.5x
RSI (14)
38.4
MomentumView details →
1D Return
+1.71%
YTD Return
+5.14%
SummaryUpdated Jun 1, 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a Boston-based healthcare company founded in 1998 that specializes in developing and commercializing treatments for gastrointestinal disorders. Originally incorporated as Microbia, Inc., the company changed its name to Ironwood Pharmaceuticals in 2008 and went public in 2010. The company has evolved from a research-focused biotechnology firm into a commercial-stage pharmaceutical company with a primary focus on gastrointestinal therapeutics, anchored by its flagship product LINZESS and a promising pipeline candidate apraglutide for rare diseases.
Similar companies
Latest newsMore news →
Ironwood Pharmaceuticals said Thomas McCourt will retire as chief executive officer and leave the board of directors, effective December 31, 2026.4d agoIronwood Pharmaceuticals appointed Tammi Gaskins as chief executive officer and elected her to its board of directors, effective January 1, 2027; her annual base salary is $775,000, with a 75% target bonus and target equity grants valued at approximately $2 million each in RSUs and PSUs.4d ago